ArticleInvestigative ophthalmology & visual science2026
RIPK3/SQSTM1-Mediated Necroptosis Activates the NLRP3 Inflammasome in Dry Eye Disease.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Dry eye disease (DED) is characterized by progressive corneal epithelial damage and chronic inflammation, yet the specific cell death mechanisms underlying epithelial loss remain unclear. This study investigated the role of RIPK3-mediated necroptosis in corneal epithelial injury and inflammation in DED. Methods: A DED murine model was established using scopolamine hydrobromide and desiccative stress. Corneal damage was assessed via fluorescein staining, SEM, and TEM. Molecular mechanisms were explored through RNA-sequencing, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis. The pathogenic role of RIPK3 and NLRP3 was validated using knockout (RIPK3-/-, NLRP3-/-), AAV-mediated overexpression, and siRNA knockdown. The therapeutic potential of the necroptosis inhibitor Necrostatin-1 was evaluated in vivo. Results: RNA-sequencing and KEGG analysis identified the TNF signaling pathway and necroptosis markers (RIPK3, MLKL) were significantly upregulated in DED corneal epithelium. RIPK3 knockdown markedly alleviated corneal epithelial damage and cell death, whereas localized RIPK3 overexpression exacerbated epithelial injury and inflammatory responses. Mechanistically, SQSTM1 act as a critical downstream mediator of RIPK3, promoting MLKL activation and necroptosis independently of canonical autophagic flux. Further analyses demonstrated that the RIPK3-SQSTM1 axis directly amplified NLRP3 inflammasome activation, thereby linking epithelial cell death to sustained inflammatory signaling. Consistently, desiccative stress induced rapid and persistent RIPK3-MLKL activation in human corneal epithelial cells, whereas Necrostatin-1 preserved corneal epithelial integrity and suppressed inflammasome activation in vivo. Conclusions: This study identifies a RIPK3-SQSTM1-NLRP3 signaling axis as a key driver of corneal epithelial damage and inflammation in DED. These findings provide mechanistic insight into ocular surface epithelial loss and highlight necroptosis as a promising therapeutic target for DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.